» Articles » PMID: 24768475

Individualised Antibiotic Dosing for Patients Who Are Critically Ill: Challenges and Potential Solutions

Abstract

Infections in critically ill patients are associated with persistently poor clinical outcomes. These patients have severely altered and variable antibiotic pharmacokinetics and are infected by less susceptible pathogens. Antibiotic dosing that does not account for these features is likely to result in suboptimum outcomes. In this Review, we explore the challenges related to patients and pathogens that contribute to inadequate antibiotic dosing and discuss how to implement a process for individualised antibiotic therapy that increases the accuracy of dosing and optimises care for critically ill patients. To improve antibiotic dosing, any physiological changes in patients that could alter antibiotic concentrations should first be established; such changes include altered fluid status, changes in serum albumin concentrations and renal and hepatic function, and microvascular failure. Second, antibiotic susceptibility of pathogens should be confirmed with microbiological techniques. Data for bacterial susceptibility could then be combined with measured data for antibiotic concentrations (when available) in clinical dosing software, which uses pharmacokinetic/pharmacodynamic derived models from critically ill patients to predict accurately the dosing needs for individual patients. Individualisation of dosing could optimise antibiotic exposure and maximise effectiveness.

Citing Articles

mNGS-based dynamic pathogen monitoring for accurate diagnosis and treatment of severe pneumonia caused by fungal infections.

Li Z, Wu C, Tang L, Liang Y, A R, Huang D Biosaf Health. 2025; 5(3):138-143.

PMID: 40078515 PMC: 11895042. DOI: 10.1016/j.bsheal.2023.04.004.


[Chinese expert consensus on diagnosis, treatment and management of critically ill patients in hematology intensive care unit (2025)].

Zhonghua Xue Ye Xue Za Zhi. 2025; 46(1):9-17.

PMID: 40059677 PMC: 11886441. DOI: 10.3760/cma.j.cn121090-20241206-00542.


The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024.

Shime N, Nakada T, Yatabe T, Yamakawa K, Aoki Y, Inoue S Acute Med Surg. 2025; 12(1):e70037.

PMID: 39996161 PMC: 11848044. DOI: 10.1002/ams2.70037.


Population Pharmacokinetics of Prolonged Infusion for Meropenem: Tailoring Dosing Recommendations for Chinese Critically Ill Patients on Continuous Renal Replacement Therapy with Consideration for Renal Function.

Peng Y, Liu Y, Cheng Z, Zhang Q, Xie F, Zhu S Drug Des Devel Ther. 2025; 19:1105-1117.

PMID: 39991086 PMC: 11844199. DOI: 10.2147/DDDT.S489603.


Editorial: Progressing the understanding and management of bloodstream infections.

Wang L, Lin B, Gong X, Yu Y Front Med (Lausanne). 2025; 12:1562934.

PMID: 39967598 PMC: 11832539. DOI: 10.3389/fmed.2025.1562934.


References
1.
Valenza G, Seifert H, Decker-Burgard S, Laeuffer J, Morrissey I, Mutters R . Comparative Activity of Carbapenem Testing (COMPACT) study in Germany. Int J Antimicrob Agents. 2012; 39(3):255-8. DOI: 10.1016/j.ijantimicag.2011.10.015. View

2.
Passarell J, Meagher A, Liolios K, Cirincione B, Van Wart S, Babinchak T . Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2007; 52(1):204-10. PMC: 2223921. DOI: 10.1128/AAC.00813-07. View

3.
Udy A, Roberts J, Lipman J . Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol. 2011; 7(9):539-43. DOI: 10.1038/nrneph.2011.92. View

4.
Dombrovskiy V, Martin A, Sunderram J, Paz H . Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007; 35(5):1244-50. DOI: 10.1097/01.CCM.0000261890.41311.E9. View

5.
Drusano G . Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003; 36(Suppl 1):S42-50. DOI: 10.1086/344653. View